o2h discovery offers a broad gamut of biochemical, biophysical, and cell-based bioassay screening services for supporting drug discovery programs of our various collaborators. To augment these services, we have incorporated SPR-based assays (surface plasmon resonance) in our portfolio using state-of-the-art Biacore T200 system.
The Biacore T200 provides real-time, label-free, affinity and kinetic analysis for various types of biomolecular interactions with high sensitivity and accuracy. This system enables our team to deliver robust, high-quality data in a time-bound manner for the screening of small molecules, biologics and NBEs (novel biological entities) at any phase of drug development. We offer various project-tailored SPR solutions which include the following:
- Fragment-based drug discovery (FBDD)
- Small molecule drug discovery
- Biotherapeutic drug discovery
(o2h discovery – Biacore T200)
o2h biology capabilities
We accelerate time-to-market using diverse scientific teams with extensive academic and industry expertise, that are committed to resource efficiency, scientific excellence, and strategic collaborations. The expanding team of biologists in India collaborates seamlessly with the UK team to provide clients with the best solution in terms of speed, cost, and talent. o2h Biology has the infrastructure and expertise to conduct a wide range of biochemical, biophysical, and cellular assays against a wide range of target classes, including enzymes, GPCRs, and ion channels. To enable these assays, the Biology department has state-of-the-art facilities for in-vitro pharmacology services, including sophisticated liquid-handling and assay-detection systems. We are expanding our infrastructure pipeline with FLIPR penta, CytoFLEX flow cytometer, and the Integra Assist Plus liquid handler.
To know more about our biology services offering or to request our brochure, please reach out to us at discovery@o2h.com.
